
Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings
Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-05-07 | English | |
| 8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-05-07 | English | |
| ARS - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-04-23 | English | |
| DEF 14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-04-23 | English | |
| 8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer) | 2026-03-24 | English | |
| 4 - AMYLYX PHARMACEUTICALS, INC. (0001658551) (Filer) | 2026-03-04 | English |
Browse filings by year
12 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
Cogent Biosciences, Inc.
A clinical-stage biotech company developing precision thera…
|
COGT | US | Manufacturing |
|
Cohance Lifesciences Limited
Global CDMO and API platform offering end-to-end solutions …
|
COHANCE | IN | Manufacturing |
|
Coherus Oncology, Inc.
Biopharmaceutical company developing and commercializing im…
|
CHRS | US | Manufacturing |
|
Colinz Laboratories ltd.
Manufactures and markets medicinal formulations across dive…
|
531210 | IN | Manufacturing |
|
COLLEGIUM PHARMACEUTICAL, INC
A biopharmaceutical company developing abuse-deterrent pain…
|
COLL | US | Manufacturing |
|
CollPlant Biotechnologies Ltd
Develops plant-derived collagen for 3D bioprinting of tissu…
|
CLGN | US | Manufacturing |
|
COMPASS Pathways plc
Develops psilocybin treatments for difficult-to-treat menta…
|
CMPS | GB | Manufacturing |
|
Compass Therapeutics, Inc.
Clinical-stage biopharma developing antibody-based therapeu…
|
CMPX | US | Manufacturing |
|
Concord Biotech Limited
R&D-driven producer of fermentation-based APIs and formulat…
|
CONCORDBIO | IN | Manufacturing |
|
Concord Drugs Limited
Develops, manufactures and markets pharmaceutical formulati…
|
538965 | IN | Manufacturing |
Amylyx Pharmaceuticals, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/31865/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=31865 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=31865 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=31865 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 31865}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Amylyx Pharmaceuticals, Inc. (id: 31865)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.